Novel Diterpene Derivative Induced Apoptosis In Melanoma Cells Via Sphingomyelinase And ERK Signaling | 12937
Epidemiology: Open Access
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
n this study, we designed and synthesized novel diterpene derivative to be investigated for anticancer activities. Our initial
screening showed that our novel derivative was cytotoxic against Melanoma cells. Our data revealed that diterpene derivative
reduced proliferation and induced apoptosis in Melanoma cells. Flow cytometric analysis showed that our novel diterpene
derivative increased the percent of Melanoma cells in G1 phase which is confirmed by increased expression levels of p21. Novel
diterpene derivative increased expression level of p53 and bax at both protein and mRNA levels and reduced expression level of
STAT-3, Bak, Bad and Mdm2. Finally, it increased sphingomyelinase signaling and ceramide formation as well as its downstream
targets ERK1/2, p38 and JNK. The induction of apoptosis by our novel diterpene derivative was dramatically reduced siRNAs
targeting acid sphingomyelinase or acid ceramidase. Inhibition of ERK1/2 with PD98059 exerted markedly reduced the novel
diterpene-induced apoptosis in Melanoma cells, p38 inhibition with SB203580 slightly lessened apoptosis and inhibition of JNK
with SP600125 had no significant effect on diterpene derivative-induced apoptosis. These results indicate that our novel diterpene
derivative induced the activation of sphingomyelinase signaling and that ERK played a pivotal role in induction of apoptosis in
Melanoma cells. In vivo studies and molecular docking experiments are now in progress for further anticancer investigations.
Ahmed M Malki has completed his Ph.D in Molecular Oncology at the age of 30 years from Edison Institute of Biotechnology, Ohio University in
USA and He completed postdoctoral studies from University of California Berkeley, USA. He is the director of Molecular therapeutics laboratory, City
of Research and Technology applications. He is currently an associate professor of Molecular Biology in Alexandria University; he has published
more than 15 papers in reputed journals and serving as an editorial board member of Journal of Genetic Syndromes and Gene Therapy, African
Journal of Biochemistry Research and Biotechnology and Molecular Biology Reviews. He also received Best Research Award, Global Breast Cancer
conference,2011, Seoul, South Korea.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals